VIAN Therapeutics
San Francisco
About VIAN Therapeutics
VIAN Therapeutics is an early-stage biotechnology company focused on transforming retinal disease treatment. With a first-in-class, non-invasive eyedrop as its lead product, VIAN aims to replace invasive injections for conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). Backed by strong preclinical data and ongoing clinical testing, VIAN is positioned to address significant unmet medical needs and disrupt the $15 billion retinal disease market.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $1.3M
- Funding stage: Seed
- Last round: Seed (Jun 2024)
- Website: viantx.com
Industries & Categories
Biotechnology, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/vian-therapeutics-74910 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.